Clinical Trial News and Research

RSS

Sanofi Pasteur and Acambis to bring West Nile vaccine to market

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive global collaboration agreement with Acambis plc, for the development and marketing of a West Nile vaccine to help fight against this serious, life-altering and potentially fatal disease.

14 Nov 2007

Hope on the horizon for hereditary angioedema sufferers

Although there is currently no treatment approved by the Federal Drug Administration (FDA) for acute attacks of hereditary angioedema (HAE) - a genetic disease causing swelling of extremities, face and internal organs that can be life-threatening - hope is on the horizon according to a team of experts presenting the latest research at the Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Dallas.

14 Nov 2007

Smoking cessation during pregnancy is focus of study

Despite warnings from experts and media campaigns marketing healthy living techniques, approximately one-third of women of childbearing age smoke cigarettes and 25-50 percent of women smoke during pregnancy.

13 Nov 2007

CellCyte Genetics receives patent on stem cell delivery method

CellCyte Genetics Corporation has announced that is has received notice of the issuance of a U.S. patent (U.S. Patent No. 7,282,222) for its unique methods and compositions approach to deliver and direct stem cells to target organs in the body.

13 Nov 2007

New target for MS treatment found using old drug

A drug currently used to treat high blood pressure and heart failure has been found to reduce the symptoms of multiple sclerosis in mice.

13 Nov 2007

Lexicon files investigational NDA for LX2931 in rheumatoid arthritis

Lexicon Pharmaceuticals, Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions.

13 Nov 2007

Trial looks at ability of insulin to limit heart-tissue damage during a heart attack

The ability of insulin to limit heart-tissue damage during a heart attack will be tested in a landmark clinical trial led by Paresh Dandona, M.D., Ph.D., University at Buffalo Distinguished Professor in the departments of Medicine and Pharmacology and Toxicology in the UB School of Medicine and Biomedical Sciences.

13 Nov 2007

FDA clears breathing tube coated with a thin layer of silver

The U.S. Food and Drug Administration has announced that it has cleared for marketing a breathing tube coated with a thin layer of silver. The coating, a material known to have antimicrobial properties, reduces the risk that patients on ventilators will acquire pneumonia while in the hospital.

13 Nov 2007

Study looks at cardiac resynchronization therapy

A randomized, controlled, multi-center trial has found that cardiac resynchronization therapy produced no improvement in peak oxygen uptake during exercise testing, the trial's primary endpoint, in patients with Class III heart failure, including mechanical problems that disrupt the heart's normal rhythm and a moderately prolonged QRS complex as demonstrated on EKG.

6 Nov 2007

Hepatitis C treatment reduces the virus but serious liver problems may progress

Patients with chronic hepatitis C and advanced liver disease who did not respond to previous standard therapy experienced significant decreases in their liver enzymes, viral levels, and liver inflammation following treatment with long-term pegylated interferon.

6 Nov 2007

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Bupropion plus counseling appears to help adolescents quit cigarette smoking in the short term

Almost one-fourth of U.S. high school students currently smoke cigarettes, according to background information in the article. Many teen smokers want to quit, but studies estimate that only about 4 percent of those who try are successful each year.

6 Nov 2007

More effective method of treating high blood pressure

Scientists at Robarts Research Institute have developed a simplified and more effective method of treating high blood pressure.

6 Nov 2007

Antioxidants inositol and inositol hexaphosphate could provide all-purpose radiation protection

Two common dietary molecules found in legumes and bran could protect DNA from the harmful effects of radiation, researchers from the University of Maryland report.

6 Nov 2007

Cancer victim comes up with a possible alternative to chemo

A cancer victim has invented a machine that could well replace traditional chemotherapy for the treatment of the disease.

5 Nov 2007

Antibody might help starve cancerous tumors

An antibody might offer a safe and effective complement to anti-cancer therapies designed to starve malignant tumors by pruning the blood vessels that feed them, researchers report in the November 2 issue of the journal Cell, a publication of Cell Press.

2 Nov 2007

Non-invasive radio waves heat up nanotubes to destroy cancer

Cancer cells treated with carbon nanotubes can be destroyed by non-invasive radio waves that heat up the nanotubes while sparing untreated tissue, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center and Rice University has shown in preclinical experiments.

2 Nov 2007

Increased glucose level is a strong risk factor for colorectal cancer

Diabetes is a very common illness that affects more than 20 million people in the U.S. and it is estimated an additional 54 million Americans have pre-diabetes, a condition that occurs when a person's blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 diabetes.

2 Nov 2007

Panzem (2-methoxyestradiol ) drug a possible candidate for breast cancer treatment

A Mayo Clinic study of a drug that has shown promise in treating sarcoma, lung and brain cancers, demonstrates that the drug may also be effective in treating breast cancer, in particular the spread of breast cancer.

2 Nov 2007

Whole parasite malaria vaccine to be manufactured for clinical trials

Sanaria Inc. and the PATH Malaria Vaccine Initiative has officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.

29 Oct 2007